Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with Pembrolizumab (KEYTRUDA®)

to patients with squamous cell cancer of the head and neck. He also expressed confidence in the potential of eganelisib in combination with pembrolizumab to improve outcomes for these patients. The MARIO-8 study is part of Infinity's broader development program for eganelisib, which includes ongoing studies in other indications such as triple-negative breast cancer and non-small cell lung cancer..